Topical P blockers are widely used and often the first line of therapy in many patients requiring treatment for glaucoma or ocular hypertension. A large proportion of these patients are or will be on long term therapy over many years. With other systemic adverse effects from topical blocker therapy already described," we decided to carry out a prospective study using a nonselective blocker to ascertain that a side effect on serum lipoprotein levels was not going undetected in so many patients on treatment for glaucoma.
Blockers taken orally for antihypertensive therapy have been shown in numerous studies to have a significant effect on serum lipoproteins. '15 Of the various types of blockers in use those that are non-selective and without intrinsic sympathomimetic activity (ISA), such as propranolol or timolol, cause the most pronounced changes, with an average increase in serum triglycerides (TG) of 32%, while high density lipoproteins (HDL) were lowered by 16%.' HDL concentration bears an inverse relation to coronary heart disease, as was pointed out by Miller and Miller and since confirmed in several prospective studies.69 The relation of TG concentration to coronary heart disease, however, remains unclear.9 10 Topical P blockers are widely used and often the first line of therapy in many patients requiring treatment for glaucoma or ocular hypertension. A large proportion of these patients are or will be on long term therapy over many years. With other systemic adverse effects from topical blocker therapy already described," we decided to carry out a prospective study using a nonselective blocker to ascertain that a side effect on serum lipoprotein levels was not going undetected in so many patients on treatment for glaucoma.
Materials and methods
This was a prospective study to see Retrospective analysis of the data was carried out to establish adequate study power to detect a difference from baseline of 0 3 mmol/l (minimum) in the TG fraction for a type II error of 0O1 (power 90%). The 95% confidence intervals for the true mean difference are -0-22 to 0-14 mmol/l at 5 weeks and -0O11 to 0-3 mmol/l at 15 weeks by the usual formula based on the t distribution.
Discussion
The risk of coronary heart disease is known to be influenced by blood lipid levels. There is a show a definite protection against coronary heart disease, and some workers consider that the benefit from blood pressure reduction may be outweighed by the adverse influence of therapy on serum lipoproteins levels. 14 Topical 13 blockers are now an established first line treatment in glaucoma. There is a significant incidence of systemic side effects (some serious), and, because of these, topical 13 blockers must be prescribed with caution in certain patients. That such small doses of drug applied to the eye can produce such systemic side effects has been attributed in part to the fact that, unlike oral 13 blockers, which are extensively metabolised in the liver before entering the general circulation,'5 topical 13 blockers are absorbed directly through the conjunctiva and nasal mucosa (first order pass). However, studies show that topically applied 13 blockers rarely reach serum levels normally considered therapeutic for antihypertensive treatment, 167 and despite this side effects are still experienced. Moreover, studies on healthy volunteers show that topical 13 blockers reduce exercise induced tachycardia and slightly decrease the resting pulse rate. '6 18 Our lipid analysis at 5 and 15 weeks should detect any change in lipid fractions if present, as the change produced by oral therapy occurred by 8 weeks and was little changed thereafter. The results show no significant adverse effect on serum lipoproteins as a consequence of topical 13 blocker therapy. This is reassuring in view of the large number ofpatients on long term therapy for raised intraocular pressure, and there appears to be no justification for using selective 13 blockers, or those drugs with ISA, on the basis of the adverse effects on serum lipoproteins shown for the oral form of therapy.
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